SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following training and mentorship of imaging specialists - SENTINUS

Maidstone and Tunbridge Wells NHS Trust0 个研究点目标入组 250 人开始时间: 2020年6月10日最近更新: 2021年1月5日

适应症

试验速览

暂无简介。

•Histologically confirmed invasive carcinoma of the breast without palpable axillary lymph nodes with planned
•primary surgical treatment.
•Normal B-mode axillary ultrasound or benign biopsy of morphologically abnormal lymph nodes.
•Participant is willing and able to give informed consent for participation in the trial.
•Aged 18 years or above.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 175
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 75

•Previous ipsilateral breast cancer treated with radiotherapy or chemotherapy or recurrent breast cancer.
•Female participant who is pregnant, lactating or planning fertility preservation during the course of the
•Allergy to contrast.
•Inflammatory or locally advanced breast cancer.
•Metastatic breast cancer.
•Inability to raise ipsilateral arm above head.
•Multiple medical co-morbidities (ASA 4 or above).
•Previous ipsilateral axillary surgery.

发起方